Search
Displaying 641–650 of 1063 results
-
#GivingTuesdayNow Featured Researcher Dr. Shannon Boye
Research NewsA Lifelong Science Nerd is Winning the Fight Against Blindness
-
asdf
-
Foundation News
The inaugural credit-based event will include education on inherited retinal diseases, physician resources, and current clinical trials.
-
Coping with COVID-19: Welcome to the “New Normal”
Beacon StoriesWe checked in with a few of the Foundation’s volunteers to get their perspective on these unprecedented times.
-
Eye Disease Studies Suggest Mediterranean Diet is Good for the Brain
Research NewsA healthy diet is also important for people with retinal conditions
-
Sue Lives Life to the Fullest and Wants to Help Others Do the Same
Beacon StoriesMeet Sue Sanger. Sue was diagnosed with retinitis pigmentosa (RP) at the age of 29 but has continued to travel, advance in her legal and political career, and more. In the following story, Sue explains, in her own words, all she has accomplished since learning she has RP and why she’s a supporter and member of the Foundation Fighting Blindness Legacy Society.
-
Why Science Is Closer Than You Think To Beating Blindness
In the PressUsing high-tech, camera-equipped eyeglasses and a healthy pair of eyes with 20/20 vision located hundreds, maybe even thousands, of miles away, a blind New York attorney has help to navigate the city’s busy streets and broken sidewalks.
-
Beacon Stories
Carolyn is a business professional and beauty industry leader in Raleigh, North Carolina. In spite of her diagnosis with retinitis pigmentosa, Carolyn pursues exactly what she wants and knows what she is purposed to do in her life.
-
Accelerating Treatments for IRDs: 2020 March Progress Report
The Foundation Fighting Blindness is pleased to provide a video recording and full transcript of the Accelerating Treatments for IRDs: 2020 March Progress Report. The presentation took place on March 27, 2020.
-
Interim Results Released for USH2A RNA Therapy Clinical Trial
Research NewsSuggestions of efficacy observed in 25 percent of participants receiving the treatment
